HIV prevention today: do we still need a vaccine? A community perspective

[...]the current tools remain inaccessible to the majority of those who need them either due to access challenges; their cost, availability, structural barriers to access as well as challenges with their use; adherence, and personal choice and preference. [...]it is believed that achieving universal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2021-11, Vol.24 (S7), p.e25806-n/a
Main Authors: Luba, Maureen, Yola, Ntando, Newells, Rob, Mwakyosi, Lilian Benjamin
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
AIDS/HIV
Clinical trials
community engagement
Coronaviruses
COVID-19 vaccines
Disease prevention
HIV
HIV vaccine
Human immunodeficiency virus
Medical research
Pandemics
Preferences
Prevention
R&D
Research & development
Supplement: Viewpoint
vaccine efficacy
Vaccines
Young adults
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the current tools remain inaccessible to the majority of those who need them either due to access challenges; their cost, availability, structural barriers to access as well as challenges with their use; adherence, and personal choice and preference. [...]it is believed that achieving universal coverage of high impact HIV prevention tools will still require developing additional tools, including a safe and effective vaccine. Since the approval of the first oral HIV prevention pill, it has become commonplace to hear declarations that we now have the tools we need to end HIV. The global partnerships and the political and financial commitment demonstrated in the development of COVID-19 vaccines and therapeutics should be replicated in the HIV vaccine research and development space. Besides the critical RV144 trial, there have been a number of efficacy trials which have been stopped for futility, including the most recent Uhambo (HVTN 702 trial) [ 6].
ISSN:1758-2652
1758-2652
DOI:10.1002/jia2.25806